Analyst, Jason R. Mills, said, "We look for ISRG to exceed seemingly conservative consensus Q2 estimates of $520M/$3.53. We model $525M/$3.64, which implies revenue/EPS growth of 23%/25%, and op-margins of 40%. We expect ISRG’s Q2 results to once again be best-of-breed in med-tech land, but believe current valuation fully accounts for strong results and modest upside to consensus."

"This isn't MAKO Surgical (Nasdaq: MAKO), but the macro isn't helpful either. With an installed base over 2200 WW vs. MAKO’s ~120 and applications for daVinci in a different stratosphere vs. MAKO, ISRG and MAKO are hardly comparable. That said, MAKO's negative Q2 pre-announcement noted a lengthening sales cycle and need for additional surgeon support, which we think is applicable to ISRG in new applications (e.g., single-site, thoracic) and new geographies (e.g., Europe, Japan)."

For an analyst ratings summary and ratings history on Intuitive Surgical click here. For more ratings news on Intuitive Surgical click here.